中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

16 records (took 0.016 seconds)

    COMBINED AGENT FOR CELL THERAPY OF CORNEAL ENDOTHELIAL CELL
    3.
    发明申请
    COMBINED AGENT FOR CELL THERAPY OF CORNEAL ENDOTHELIAL CELL 审中-公开
    组合细胞治疗角膜内皮细胞的药物

    公开(公告)号：US20160317528A1

    公开(公告)日：2016-11-03

    申请号：US15108355

    申请日：2013-12-27

    Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION ,  THE DOSHISHA ,  SENJU PHARMACEUTICAL CO., LTD.

    Inventor： Noriko KOIZUMI ,  Naoki OKUMURA ,  Shigeru KINOSHITA

    IPC: A61K31/4745 ,  A61K9/00 ,  A61K35/44 ,  A61K35/30

    CPC classification number: A61K31/4745 ,  A61K9/0048 ,  A61K35/30 ,  A61K35/44 ,  A61K45/06

    Abstract: The present invention provides an agent for treating or preventing a disease, a disorder or a condition of a corneal endothelium, said agent comprising a corneal endothelial cell and a myosin II-specific inhibitor. More specifically, the myosin II-specific inhibitor is blebbistatin. The disease, the disorder or the condition is typically a disorder associated with Fuchs endothelial corneal dystrophy or corneal endothelial dysfunction (bullous keratopathy). Also provided is a method for treating or preventing a corneal endothelial disease, said method comprising a step of administering an effective amount of a myosin II-specific inhibitor together with a corneal endothelial cell to a subject.

    Abstract translation: 本发明提供了用于治疗或预防角膜内皮的疾病，病症或病症的药剂，所述药物包含角膜内皮细胞和肌球蛋白II特异性抑制剂。 更具体地说，肌球蛋白II特异性抑制剂是blebbistatin。 疾病，病症或病症通常是与Fuchs内皮角膜营养不良或角膜内皮功能障碍（大疱性角膜病）相关的病症。 还提供了治疗或预防角膜内皮细胞疾病的方法，所述方法包括向受试者施用有效量的肌球蛋白II特异性抑制剂与角膜内皮细胞一起的步骤。

    CORNEAL ENDOTHELIAL CELL MARKER
    4.
    发明申请
    CORNEAL ENDOTHELIAL CELL MARKER 审中-公开
    角膜内皮细胞标记

    公开(公告)号：US20160266114A1

    公开(公告)日：2016-09-15

    申请号：US14908036

    申请日：2014-07-28

    Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION ,  THE DOSHISHA ,  SENJU PHARMACEUTICAL CO., LTD.

    Inventor： Noriko KOIZUMI ,  Naoki OKUMURA ,  Hiroatsu HIRANO ,  Shigeru KINOSHITA ,  Morio UENO

    IPC: G01N33/569 ,  A61K35/30

    CPC classification number: G01N33/56966 ,  A61K35/30 ,  C12N5/0621 ,  G01N2333/705 ,  G01N2333/70596

    Abstract: The purpose of the present invention is to provide a method of purification and preparation of cultured corneal endothelial cells, and in particular, to provide cell surface markers for use in corneal endothelial cells not including transformed cells. Provided are cell markers for distinguishing normal cells and transformed cells, in particular normal and transformed corneal endothelium cells. These cell markers relate to specific cell surface markers, for example, to a normal corneal endothelial surface marker such as CD166, and a transformed cell surface marker such as CD73. By using the transformed cell surface marker such as CD73 to remove transformed cells by sorting, it becomes possible to improve purity of a normal cultured corneal endothelium. By using normal corneal endothelial surface marker such as CD166, or by combined use with the transformed cell surface marker, it becomes possible to provide a means for verifying the purity of a prepared corneal endothelium.

    Abstract translation: 本发明的目的是提供一种纯化和制备角膜内皮细胞的方法，特别是提供用于不包括转化细胞的角膜内皮细胞的细胞表面标志物。 提供用于区分正常细胞和转化细胞的细胞标志物，特别是正常和转化的角膜内皮细胞。 这些细胞标志物涉及特定细胞表面标志物，例如与正常角膜内皮表面标志物如CD166和转化的细胞表面标志物如CD73相关。 通过使用转化的细胞表面标记如CD73通过分选来除去转化的细胞，可以提高正常培养的角膜内皮的纯度。 通过使用正常的角膜内皮表面标记如CD166，或通过与转化的细胞表面标记物的组合使用，可以提供一种验证制备的角膜内皮的纯度的方法。

    FUNCTIONAL HUMAN CORNEAL ENDOTHELIAL CELLS AND APPLICATION THEREOF
    5.
    发明公开
    FUNCTIONAL HUMAN CORNEAL ENDOTHELIAL CELLS AND APPLICATION THEREOF 审中-公开

    公开(公告)号：US20230257700A1

    公开(公告)日：2023-08-17

    申请号：US17802824

    申请日：2021-02-26

    Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION

    Inventor： Shigeru KINOSHITA ,  Junji HAMURO ,  Chie SOTOZONO ,  Morio UENO ,  Munetoyo TODA

    IPC: C12N5/079 ,  A61P27/02

    CPC classification number: C12N5/0621 ,  A61P27/02 ,  C12N2501/11 ,  C12N2501/727

    Abstract: To provide a cell trait assay technique for identifying cultured human corneal endothelium cells of which early clinical effect manifestation and a long-term stable clinical effect are confirmed, in clinical trials. Provided is a method of manufacturing a functional human corneal endothelial cell capable of eliciting a human corneal function when infused into an anterior chamber of a human eye, the method comprising the step of proliferating and/or differentiating or maturing a corneal endothelial progenitor cell under a culture condition capable of minimizing culture stress, such as proliferation stress. Further, provided is a functional human corneal endothelial cell in which expression of a functional protein leading to a corneal endothelial (cell) functional property leading to improvement on corneal opacity and hydrous edema, resulting in continuous and long-term retention of corneal endothelial tissue cell density and improvement on visual acuity is recognized or in which a protein that inhibits the corneal endothelial (cell) functional property is not elicited or is reduced.

    CORNEAL ENDOTHELIUM ECM THERAPEUTIC MEDICAMENTS
    7.
    发明申请
    CORNEAL ENDOTHELIUM ECM THERAPEUTIC MEDICAMENTS 审中-公开
    CORNEAL内皮细胞治疗药物

    公开(公告)号：US20160158210A1

    公开(公告)日：2016-06-09

    申请号：US14907881

    申请日：2013-07-30

    Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION ,  THE DOSHISHA ,  SENJU PHARMACEUTICAL CO., LTD.

    Inventor： Noriko KOIZUMI ,  Naoki OKUMURA ,  Shigeru KINOSHITA

    IPC: A61K31/4439 ,  A61K9/00 ,  C12N15/113

    CPC classification number: A61K31/4439 ,  A61K9/0048 ,  A61K31/4402 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/4745 ,  A61K31/519 ,  A61K39/395 ,  A61K45/06 ,  C12N15/1136 ,  C12N2310/14 ,  C12N2320/30 ,  A61K2300/00

    Abstract: The present invention provides medicaments for treating or preventing a disease, disorder, or condition associated with extracellular matrix (ECM) abnormality in a corneal endothelium, wherein the medicaments comprise a TGF-beta signal inhibiting agent. More specifically, this disease, disorder, or condition is a disorder associated with Fuchs' endothelial corneal dystrophy. Such a disorder includes photophobia, blurred vision, vision disorder, eye pain, lacrimation, hyperemia, pain, bullous keratopathy, ophthalmic unpleasantness, a decrease in contrast, glare, edema in corneal stroma, bullous keratopathy, corneal opacity, and the like. A preferable TGF-beta signal inhibiting agent includes 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide.

    Abstract translation: 本发明提供用于治疗或预防与角膜内皮细胞外基质（ECM）异常相关的疾病，病症或病症的药物，其中所述药物包含TGF-β信号抑制剂。 更具体地，这种疾病，病症或病症是与福克斯内皮角膜营养不良相关的病症。 这种病症包括畏光，视力模糊，视力障碍，眼痛，流泪，充血，疼痛，大疱性角膜病，眼睛不适，对比度下降，眩光，角膜基质水肿，大疱性角膜病，角膜不透明度等。 优选的TGF-β信号抑制剂包括4- [4-（1,3-苯并间二氧杂环戊烯-5-基）-5-（2-吡啶基）-1H-咪唑-2-基]苯甲酰胺。

    HUMAN FUNCTIONAL CORNEAL ENDOTHELIAL CELL AND APPLICATION THEREOF
    8.
    发明申请
    HUMAN FUNCTIONAL CORNEAL ENDOTHELIAL CELL AND APPLICATION THEREOF 有权

    公开(公告)号：US20210046124A1

    公开(公告)日：2021-02-18

    申请号：US17074912

    申请日：2020-10-20

    Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION

    Inventor： Shigeru KINOSHITA ,  Junji HAMURO ,  Chie SOTOZONO ,  Morio UENO

    IPC: A61K35/30 ,  C12N5/079 ,  A61K35/00

    Abstract: The present invention complete a technique of treating a corneal disorder or disease by infusion into an anterior chamber of human eyes. Specifically, the present invention based on the findings discovered that cultured human corneal endothelial cells are comprised of a plurality of subpopulations, most of them are not suitable for infusion into patients. The above-described subject was overcome by providing, as a medicament, functionally high grade quality of cells having the function of mature differentiated human corneal endothelial cells which is a specific subpopulation and characterized by their biochemical and functional phenotypes. The present invention provides such a functional mature differentiated corneal endothelial cells, medicament comprising the same, and manufacturing method, quality control and techniques related thereto.

    APPLICATION OF LAMININ TO CORNEAL ENDOTHELIAL CELL CULTURE
    9.
    发明申请
    APPLICATION OF LAMININ TO CORNEAL ENDOTHELIAL CELL CULTURE 审中-公开
    LAMININ在角膜内皮细胞培养中的应用

    公开(公告)号：US20170002318A1

    公开(公告)日：2017-01-05

    申请号：US15100147

    申请日：2014-11-26

    Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION ,  THE DOSHISHA ,  SENJU PHARMACEUTICAL CO., LTD.

    Inventor： Noriko KOIZUMI ,  Naoki OKUMURA ,  Shigeru KINOSHITA ,  Friedrich E. KRUSE ,  Ursula SCHLOETZER-SCHREHARDT

    IPC: C12N5/079 ,  A61K35/30

    CPC classification number: C12N5/0621 ,  A61K35/30 ,  C12N2533/52

    Abstract: The present invention provides a method of culturing corneal endothelial cells. More specifically, the present invention provides a composition for culturing or growing corneal endothelial cells, comprising at least one agent consisting of laminins and fragments thereof which express in corneal endothelial cells. Specifically, the present invention can comprise laminin 511 (alpha5 beta1 gamma1) and laminin 512 (alpha5 beta2 gamma 1). The present invention further provides a culture container for corneal endothelial cells, which is coated with the composition of the present invention. Furthermore, the present invention provides a method for culturing corneal endothelial cells comprising the step of using the composition or the container of the present invention to culture the corneal endothelial cells.

    Abstract translation: 本发明提供了培养角膜内皮细胞的方法。 更具体地说，本发明提供了一种用于培养或生长角膜内皮细胞的组合物，其包含至少一种由在角膜内皮细胞中表达的层粘连蛋白及其片段组成的试剂。 具体地，本发明可以包含层粘连蛋白511（α5β1γ1）和层粘连蛋白512（α5β2γ1）。 本发明还提供了用本发明的组合物涂覆的角膜内皮细胞培养容器。 此外，本发明提供了一种培养角膜内皮细胞的方法，包括使用本发明的组合物或容器培养角膜内皮细胞的步骤。

Patent Agency Ranking